
**APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY
– STATUS UPDATE**

Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in the announcements of OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the "**Company**") dated 3 May 2016, 6 May 2016, 8 July 2016, 8 August 2016, 15 August 2016, 16 September 2016, 13 October 2016, 21 October 2016, 14 November 2016, 24 November 2016, 15 December 2016, 13 January 2017, 11 March 2017, 29 April 2017, 17 May 2017, 16 June 2017, 29 June 2017, 13 July 2017, 22 August 2017, 28 September 2017, 25 October 2017, 22 November 2017, 28 December 2017, 24 January 2018, 28 February 2018, 27 March 2018, 30 April 2018 and 28 May 2018 (the "**Announcements**"), in relation to, *inter alia*, the appointment of receivers over certain subsidiaries of the Company.

As required under the applicable Catalist Rules, the Board of Directors of the Company refers to the Announcements and wishes to provide the following update to its shareholders on the receivership over certain subsidiaries of the Company and the progress of the sale of the Australian properties:

As announced on 30 April 2018, Andrew Aathar has filed an appeal against the decision of the Judge that the purported approval of Aathar's Voluntary Arrangement at the October Creditors' Meeting should be revoked arising from material irregularities, and that no further creditors' meeting should be called in respect of Aathar's Voluntary Arrangement. The hearing of Andrew Aathar's appeal has been fixed for a date between 25 to 28 February 2019.

Save for the foregoing, the Board of Directors of the Company wishes to inform shareholders that there are no material updates on the receivership over certain subsidiaries of the Company and the progress of the sale of the Australian properties.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board

Dr Wong Weng Hong
Chief Executive Officer and Executive Director
26 June 2018

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com